Published in Int J Pept Protein Res on October 01, 1980
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun (1989) 3.03
Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70
Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet (1974) 2.65
Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem (1984) 1.96
Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology (1997) 1.87
Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS (1990) 1.77
Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin. Gastroenterology (1976) 1.74
A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry (2002) 1.73
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet (1973) 1.68
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys (2002) 1.61
Hypothalamic regulatory hormones. Annu Rev Biochem (1978) 1.60
Klüver-Bucy syndrome after bilateral selective damage of amygdala and its cortical connections. J Neuropsychiatry Clin Neurosci (1998) 1.59
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia (2008) 1.51
Solid phase synthesis of growth hormone-release inhibiting factor. Biochem Biophys Res Commun (1973) 1.44
Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. Arch Biochem Biophys (1989) 1.41
Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem (1997) 1.33
Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene (1994) 1.30
Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology (1991) 1.30
Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science (1982) 1.29
Radioimmunoassay for GH-release inhibiting hormone. Proc Soc Exp Biol Med (1975) 1.27
Growth hormone release inhibiting hormone in acromegaly. Br Med J (1974) 1.24
LH-RH agonists and antagonists. Int J Gynaecol Obstet (1980) 1.24
Radioimmunoassay of somatostatin. Metabolism (1978) 1.22
Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion. J Clin Invest (1976) 1.22
Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci (1991) 1.18
Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol (1998) 1.16
Purification and characterization of human recombinant interleukin-1 beta. J Biol Chem (1987) 1.16
Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer (2004) 1.15
Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) (1984) 1.15
Co-localization of vasoactive intestinal peptide (VIP) and enkephalins in chromaffin cells of the adrenal gland of amphibia. Stimulation of corticosteroid production by VIP. Life Sci (1983) 1.14
Postoperative mutism in neurosurgery. Report of two cases. J Neurosurg (1994) 1.13
Somatostatin receptor-mediated signaling in smooth muscle. Activation of phospholipase C-beta3 by Gbetagamma and inhibition of adenylyl cyclase by Galphai1 and Galphao. J Biol Chem (1996) 1.12
The interaction of growth hormone releasing hormone with other hypothalamic hormones on the release of anterior pituitary hormones. Clin Endocrinol (Oxf) (1986) 1.12
Comparison of the distribution of dynorphin systems and enkephalin systems in brain. Science (1982) 1.11
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem (1976) 1.10
Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol (1993) 1.09
Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol (1998) 1.07
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry (1978) 1.07
Synthesis and biological actions of prosomatostatin. Proc Natl Acad Sci U S A (1980) 1.07
Relationship between quality of life and mood in long-term survivors of breast cancer treated with mastectomy. Support Care Cancer (1997) 1.07
Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat. Peptides (1983) 1.07
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest (1997) 1.06
An analog of enkephalin having prolonged opiate-like effects in vivo. Science (1977) 1.06
A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol (2011) 1.05
Proceedings: Effect of somatostatin on motilin levels and gastric emptying. Gut (1975) 1.05
Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology (1985) 1.03
Comparison of methionine-enkephalin and morphine in the stimulation of gastric acid secretion in the dog. Gastroenterology (1980) 1.02
Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy. Biochemistry (1994) 1.02
Glucagon control of fasting glucose in man. Lancet (1974) 1.02
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action. Proc Natl Acad Sci U S A (1982) 1.02
Gastrin secretion from human antral G cells in culture. Gastroenterology (1990) 1.00
Corticotropin-releasing factor stimulates accumulation of adenosine 3', 5'-monophosphate in rat pituitary corticotrophs. Science (1982) 1.00
Carrier-mediated transport of enkephalins and N-Tyr-MIF-1 across blood-brain barrier. Am J Physiol (1986) 0.99
Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology (1985) 0.99
Hindbrain GRP receptor blockade antagonizes feeding suppression by peripherally administered GRP. Am J Physiol (1996) 0.99
Inhibition of pancreatic secretion by enkephalin and morphine in dogs. Gastroenterology (1978) 0.99
Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest (1995) 0.98
Solution structure of the Grb2 N-terminal SH3 domain complexed with a ten-residue peptide derived from SOS: direct refinement against NOEs, J-couplings and 1H and 13C chemical shifts. J Mol Biol (1997) 0.98
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res (1997) 0.98
Recent approaches to fertility control based on derivative of LH-RH. Vitam Horm (1980) 0.97
An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology (1998) 0.97
Reversal of somatostatin inhibition of insulin and glucagon secretion. Diabetes (1976) 0.97
The somatostatin receptor subtype on rat enterochromaffinlike cells. Gastroenterology (1994) 0.97
Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol (Oxf) (1984) 0.97
Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation (1997) 0.96
Gonadotrophin releasing hormone analogues. Ann Clin Res (1978) 0.96
Differential binding of somatostatin agonists to somatostatin receptors in brain and adenohypophysis. Neuroendocrinology (1987) 0.96
Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release. Biochem Biophys Res Commun (1977) 0.96
Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun (1977) 0.95
Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clin Endocrinol (Oxf) (1979) 0.95
Adrenomedullin, amylin, calcitonin gene-related peptide and their fragments are potent inhibitors of gastric acid secretion in rats. Eur J Pharmacol (1997) 0.95
Comparison of the effect of somatostatin on gastrointestinal function in the conscious and anaesthetized cat and on the isolated cat pancreas. J Physiol (1977) 0.95
Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells. J Pharmacol Exp Ther (1998) 0.95
Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A (1982) 0.95
Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol (1990) 0.94
Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg (1996) 0.94
Ventricular enlargement after closed head injury. Arch Neurol (1981) 0.94
An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs. Acta Endocrinol (Copenh) (1977) 0.94
Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res (1997) 0.94
Inhibition of adenosine 3',5'-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone. Biochem Biophys Res Commun (1974) 0.94
Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J. FEBS Lett (1990) 0.94
Solid phase synthesis of peptides containing the CH2NH peptide bond isostere. Peptides (1987) 0.93
Effect of somatostatin on myoelectrical activity of small bowel. Am J Physiol (1978) 0.93
Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol (1996) 0.93
Isolation and structure of pro-methionine-enkephalin: Potential enkephalin precursor from porcine hypothalamus. Proc Natl Acad Sci U S A (1979) 0.93
Effects of porcine and rat endothelin and an analog on blood pressure in the anesthetized cat. Eur J Pharmacol (1989) 0.93
Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. Mol Pharmacol (1993) 0.92
Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem (1999) 0.92
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys (1995) 0.92
Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am J Physiol (1997) 0.92